Lakewood-Amedex Biotherap... (LABT)
Lakewood-Amedex Biotherapeutics Inc. (LABT) Stock Price, Analysis & Data
| Bid | 1.55 |
| Market Cap | 5.2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.23M |
| Beta | n/a |
| EPS (ttm) | -3.98 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | -0.54 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.68 |
| Volume | 14,855 |
| Avg. Volume (20D) | 1,495,875 |
| Open | 2.23 |
| Previous Close | 2.30 |
| Day's Range | 2.17 - 2.26 |
| 52-Week Range | 1.66 - 98.20 |
| Analyst | n/a |
| Price Target | 12 (453.00%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LABT
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. Th...
Financial Performance
In 2025, Lakewood-Amedex Biotherapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -3.85M, a decrease of -20.76%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for LABT stock is "null". The 12-month stock price forecast is 12, which is upside of 453% from the latest price.
Stock Forecasts